- Home
- VNDA vs ATAI Comparison
VNDA vs ATAI Comparison
Compare VNDA & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- ATAI
- Stock Information
- Founded
- VNDA 2002
- ATAI 2018
- Country
- VNDA United States
- ATAI Germany
- Employees
- VNDA N/A
- ATAI N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- ATAI Health Care
- Exchange
- VNDA Nasdaq
- ATAI Nasdaq
- Market Cap
- VNDA 282.8M
- ATAI 271.6M
- IPO Year
- VNDA 2006
- ATAI 2021
- Fundamental
- Price
- VNDA $4.88
- ATAI $1.40
- Analyst Decision
- VNDA Strong Buy
- ATAI Strong Buy
- Analyst Count
- VNDA 2
- ATAI 4
- Target Price
- VNDA $16.50
- ATAI $9.00
- AVG Volume (30 Days)
- VNDA 652.5K
- ATAI 2.1M
- Earning Date
- VNDA 05-07-2025
- ATAI 03-17-2025
- Dividend Yield
- VNDA N/A
- ATAI N/A
- EPS Growth
- VNDA N/A
- ATAI N/A
- EPS
- VNDA N/A
- ATAI N/A
- Revenue
- VNDA $198,772,000.00
- ATAI $308,000.00
- Revenue This Year
- VNDA $14.36
- ATAI N/A
- Revenue Next Year
- VNDA $44.53
- ATAI $20.00
- P/E Ratio
- VNDA N/A
- ATAI N/A
- Revenue Growth
- VNDA 3.18
- ATAI N/A
- 52 Week Low
- VNDA $3.71
- ATAI $0.78
- 52 Week High
- VNDA $6.75
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- VNDA 52.81
- ATAI 37.68
- Support Level
- VNDA $4.84
- ATAI $1.33
- Resistance Level
- VNDA $5.04
- ATAI $1.48
- Average True Range (ATR)
- VNDA 0.22
- ATAI 0.10
- MACD
- VNDA -0.00
- ATAI -0.02
- Stochastic Oscillator
- VNDA 45.61
- ATAI 9.65
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.